Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Deliveliotis

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Urology|December 1, 1996
Does free to total ratio of prostate-specific antigen alter decision-making on prostatic biopsy?G Alivizatos, C Deliveliotis, D Mitropoulos, et al.
Urology|July 22, 1998
Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxelM A Dimopoulos, C Deliveliotis, L A Moulopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)|May 10, 2011
The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancerA Bamias, E Manios, A Karadimou, et al.
BJU International|April 23, 2002
Biofeedback vs verbal feedback as learning tools for pelvic muscle exercises in the early management of urinary incontinence after radical prostatectomyD L Floratos, G S Sonke, C A Rapidou, et al.
The British Journal of Cancer. Supplement|July 1, 1990
Immunohistochemical and immunocytochemical study of bladder carcinomas using the epithelium-specific, tumour-associated monoclonal antibodies HMFG1 and AUA1E Anagnostaki, D Skarlos, N Tamvakis, et al.
Urology|August 2, 2003
Prognostic significance of CA 125, CD44, and epithelial membrane antigen in renal cell carcinomaA Bamias, M Chorti, C Deliveliotis, et al.
Urology|January 26, 2005
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessmentE Efstathiou, G Bozas, A Kostakopoulos, et al.
Urology|December 31, 1997
Oral estramustine and oral etoposide for hormone-refractory prostate cancerM A Dimopoulos, C Panopoulos, C Bamia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2000
Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology GroupM A Dimopoulos, C Bakoyannis, V Georgoulias, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2003
Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology GroupA Bamias, G Aravantinos, C Deliveliotis, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Urology|December 1, 1996
Does free to total ratio of prostate-specific antigen alter decision-making on prostatic biopsy?G Alivizatos, C Deliveliotis, D Mitropoulos, et al.
Urology|July 22, 1998
Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxelM A Dimopoulos, C Deliveliotis, L A Moulopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)|May 10, 2011
The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancerA Bamias, E Manios, A Karadimou, et al.
BJU International|April 23, 2002
Biofeedback vs verbal feedback as learning tools for pelvic muscle exercises in the early management of urinary incontinence after radical prostatectomyD L Floratos, G S Sonke, C A Rapidou, et al.
The British Journal of Cancer. Supplement|July 1, 1990
Immunohistochemical and immunocytochemical study of bladder carcinomas using the epithelium-specific, tumour-associated monoclonal antibodies HMFG1 and AUA1E Anagnostaki, D Skarlos, N Tamvakis, et al.
Urology|August 2, 2003
Prognostic significance of CA 125, CD44, and epithelial membrane antigen in renal cell carcinomaA Bamias, M Chorti, C Deliveliotis, et al.
Urology|January 26, 2005
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessmentE Efstathiou, G Bozas, A Kostakopoulos, et al.
Urology|December 31, 1997
Oral estramustine and oral etoposide for hormone-refractory prostate cancerM A Dimopoulos, C Panopoulos, C Bamia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2000
Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology GroupM A Dimopoulos, C Bakoyannis, V Georgoulias, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2003
Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology GroupA Bamias, G Aravantinos, C Deliveliotis, et al.
Pageof 9